Team

The ReMedys' team is composed of professionals from the biopharmaceutical industry. They are responsible for planning and executing program deliverables and timelines, as well as overseeing the overall strategy of the foundation.

Foundation Board

Teresa Giovannini

President of the Board, Attorney-at-Law, Founding Partner at LALIVE Law Firm, Geneva, Zurich & London

Ms Giovannini specialises in international and comparative law.


Prof. Dr. Johan Auwerx

Designated Board Member

Johan Auwerx is Professor at the Swiss Federal Institute of Technology Lausanne (EPFL). He is using systems genetics approaches to understand the aging process. His research spurred the development of new drugs for the treatment of non-communicable diseases. Johan Auwerx is was elected as a member of EMBO and has received many scientific prizes, including the prestigious Marcel Benoist prize. He is the founder of several biotech companies.

Prof. Dr. Markus Weber

Director of Muskelzentrum/ALS clinic, St. Gallen Cantonal Hospital, Switzerland

Dr. Weber is founder of the ALS clinic in St. Gallen in 2006 and the ALS clinic at the University Hospital Basel and acting chief of all ALS research projects in St. Gallen and Basel.

Dr. Kostas Kaloulis

ReMedys Founder, Board Member
Partnerships

Dr. Kaloulis holds a PhD in Molecular Embryology from the University of Geneva, Switzerland. Serial entrepreneur and currently venture partner with ND capital, he brings to ReMedys a successful track record in biotechnology, pharmaceutical industry and research. He is currently CEO of EVIR Therapeutics and Epicure Biotechnologies and former CEO of Arctos Medical (sold to Novartis).

Dr. Bernard Schneider

ReMedys Founder, Board Member
New Projects

Dr. Schneider is heading the Bertarelli Gene Therapy Platform at the Swiss Federal Institute of Technology Lausanne (EPFL). He is lecturer at the EPFL School of Life Sciences. 

Dr. Michel Dreano 

ReMedys Founder and Board Member


Dr. Dreano graduated from the University of Burgundy (PhD in Cell Biology) and from University of Paris 7/Institute Pasteur, France (PhD in Microbiology). He brings to ReMedys more than 35 years professional experience in biotechnology and pharmaceuticals industry, including at Serono Inc and Merck KGaA. He is also one of the co-founders of the publicly traded Relief Therapeutics SA, where he served as CFO/COO.

Management Team

Dr. Harald Petry

Head of Research & Development

Dr. Petry has 25+ years of experience in the field of gene therapy. As head of R&D at uniQure he was responsible for non-clinical development of Glybera (lipoprotein lipase deficiency) and initial non-clinical R&D of Hemgenix (haemophilia B).

Patrik Richard

Head of Operations

Attorney-at-Law and Mediator

Mr. Richard has over 20 years of experience working in and with biotech and medtech companies.

healthspan KHARIS program management team

Prof. Dr. Johan Auwerx

Professor at the EPFL


Dr. G. Mani Subramaniam

CEO of OrsoBio

Dr. Kostas Kaloulis

ReMedys Board Member 

Dr. Zhaoshi Jiang

Senior Vice President for Data Science at BioMap

neurogeneration ALS program management team

Dr. Bernard Schneider

Head of Research 


Dr. Harald Petry

Head of Development

Dr. Kostas Kaloulis

ReMedys Board Member

Patrik Richard

Head of Operations
Attorney-at-law, Mediator

Our current and past Partners and Supporters

The work at ReMedys is made possible by the support we receive from experts, donors, partners, industry, hospitals, public bodies, and research institutions. 

  • Kantonsspital St. Gallen, Muskelzentrum / ALS Klinik
  • Weizmann Institute of Science, Israel
  • Swiss Federal Institute of Technology (EPFL), Lausanne, Switzerland
  • Ludwig Center for Cancer Research of the University of Lausanne
  • Relief Therapeutics, Geneva, Switzerland
  • IsrA.L.S., Haifa, Israel
  • Prize4Life, Cambridge, MA, USA


If your organization would like to become involved in our initiative, please contact us. We would like to hear from you.